Study #2024-1642
A phase 3 multicenter, randomized, open-label study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in the first-line treatment of patients with locoregional recurrence of squamous cell carcinoma of the head and neck (HNSCC) with no distant metastases
MD Anderson Study Status
Enrolling
Treatment Agent
Combination Product: ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
Description
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn about the safety of ASP-1929 PIT in combination with pembrolizumab. Researchers will compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy (carboplatin or cisplatin, plus 5-fluorouracil or paclitaxel or docetaxel) according to physician's choice (control arm). The overall primary study hypothesis being tested is whether ASP-1929 PIT plus pembrolizumab combination treatment improves the overall survival (OS) of the population defined by the inclusion/exclusion criteria over the control arm.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Head and Neck Squamous Cell Carcinoma
Study phase:
Phase III
Physician name:
Ann Gillenwater
Department:
Head & Neck Surgery
For general questions about clinical trials:
1-855-671-3635
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.